Lyra Therapeutics
Biotechnology, 480 Arsenal St, Watertown, , 2472, Massachusetts, United States, 51-200 Employees
Who is LYRA THERAPEUTICS
Lyra Therapeutics is a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), an inflammatory disease of the par...
Read More
-
Headquarters: 480 Arsenal St, Watertown, Massachusetts, 2472, United States
-
Date Founded: 2018
-
Employees: 51-200
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
-
CEO:
Holly Freiner
Email
Phone
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from LYRA THERAPEUTICS
Lyra Therapeutics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Lyra Therapeutics
Answer: Lyra Therapeutics's headquarters are located at 480 Arsenal St, Watertown, , 2472, Massachusetts, United States
Answer: Lyra Therapeutics's official website is https://lyratx.com
Answer: Lyra Therapeutics's revenue is $10 Million to $25 Million
Answer: Lyra Therapeutics's SIC: 2834
Answer: Lyra Therapeutics's NAICS: 325412
Answer: Lyra Therapeutics has 51-200 employees
Answer: Lyra Therapeutics is in Biotechnology
Answer: Lyra Therapeutics contact info: Phone number: Website: https://lyratx.com
Answer: Lyra Therapeutics is a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities. Building on expertise in materials science, drug development and formulation, Lyra has developed proprietary technology that is designed to deliver medicines directly precisely and consistently to the affected tissue for sustained periods with a single administration. Our product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, in-office procedure and intended to deliver up to six months of continuous mometasone furoate drug therapy to the sinonasal passages for the treatment of CRS.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month